Top

Published in:

04-10-2023 | Glioblastoma | Research

Risk of developing glioblastoma following non-CNS primary cancer: a SEER analysis between 2000 and 2018

Authors: David Y. A. Dadey, Zachary A. Medress, Mayur Sharma, Beatrice Ugiliweneza, Dengzhi Wang, Adrian Rodrigues, Jonathon Parker, Eric Burton, Brian Williams, Summer S. Han, Maxwell Boakye, Stephen Skirboll

Published in: Journal of Neuro-Oncology | Issue 3/2023

Abstract

Background

Patients with a prior malignancy are at elevated risk of developing subsequent primary malignancies (SPMs). However, the risk of developing subsequent primary glioblastoma (SPGBM) in patients with a prior cancer history is poorly understood.

Methods

We used the Surveillance, Epidemiology, and End Results (SEER) database and identified patients diagnosed with non-CNS malignancy between 2000 and 2018. We calculated a modified standardized incidence ratio (M-SIR), defined as the ratio of the incidence of SPGBM among patients with initial non-CNS malignancy to the incidence of GBM in the general population, stratified by sex latency, and initial tumor location.

Results

Of the 5,326,172 patients diagnosed with a primary non-CNS malignancy, 3559 patients developed SPGBM (0.07%). Among patients with SPGBM, 2312 (65.0%) were men, compared to 2,706,933 (50.8%) men in the total primary non-CNS malignancy cohort. The median age at diagnosis of SPGBM was 65 years. The mean latency between a prior non-CNS malignancy and developing a SPGBM was 67.3 months (interquartile range [IQR] 27–100). Overall, patients with a primary non-CNS malignancy had a significantly elevated M-SIR (1.13, 95% CI 1.09–1.16), with a 13% increased incidence of SPGBM when compared to the incidence of developing GBM in the age-matched general population. When stratified by non-CNS tumor location, patients diagnosed with primary melanoma, lymphoma, prostate, breast, renal, or endocrine malignancies had a higher M-SIR (M-SIR ranges: 1.09–2.15). Patients with lung cancers (M-SIR 0.82, 95% CI 0.68–0.99), or stomach cancers (M-SIR 0.47, 95% CI 0.24–0.82) demonstrated a lower M-SIR.

Conclusion

Patients with a history of prior non-CNS malignancy are at an overall increased risk of developing SPGBM relative to the incidence of developing GBM in the general population. However, the incidence of SPGBM after prior non-CNS malignancy varies by primary tumor location, with some non-CNS malignancies demonstrating either increased or decreased predisposition for SPGBM depending on tumor origin. These findings merit future investigation into whether these relationships represent treatment effects or a previously unknown shared predisposition for glioblastoma and non-CNS malignancy.

Available only for authorised users

Frodin JE, Ericsson J, Barlow L (1997) Multiple primary malignant tumors in a national cancer registry–reliability of reporting. Acta Oncologica (Stockholm, Sweden) 36(5):465–469CrossRefPubMed

Salminen E, Pukkala E, Teppo L (1999) Second cancers in patients with brain tumours–impact of treatment. Eur J Cancer 35(1):102–105CrossRefPubMed

Lee KD, Chen CY, Huang HJ et al (2015) Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year period. BMC Cancer. 15:393. https://doi.org/10.1186/s12885-015-1426-3CrossRefPubMedPubMedCentral

Su VY, Liu CJ, Chen YM et al (2017) Risk of second primary malignancies in lung cancer survivors—the influence of different treatments. Target Oncol 12(2):219–227. https://doi.org/10.1007/s11523-016-0459-0CrossRefPubMed

Hung MH, Liu CJ, Teng CJ et al (2016) Risk of second non-breast primary cancer in male and female breast cancer patients: a population-based cohort study. PLoS ONE 11(2):e0148597. https://doi.org/10.1371/journal.pone.0148597CrossRefPubMedPubMedCentral

Yang J, Li S, Lv M et al (2017) Risk of subsequent primary malignancies among patients with prior colorectal cancer: a population-based cohort study. Onco Targets Ther 10:1535–1548. https://doi.org/10.2147/ott.S129220CrossRefPubMedPubMedCentral

Kauffmann RM, Wang L, Phillips S, Idrees K, Merchant NB, Parikh AA (2014) Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors. J Ann Surg Oncol 21(11):3422–3428. https://doi.org/10.1245/s10434-014-3774-7CrossRef

Cho YY, Lim J, Oh CM et al (2015) Elevated risks of subsequent primary malignancies in patients with thyroid cancer: a nationwide, population-based study in Korea. Cancer 121(2):259–268. https://doi.org/10.1002/cncr.29025CrossRefPubMed

Gessler F, Zappi J, Konczalla J et al (2017) Secondary glioblastoma: molecular and clinical factors that affect outcome after malignant progression of a lower grade tumor. World Neurosurgery 102:49–55. https://doi.org/10.1016/j.wneu.2017.02.104CrossRefPubMed

10.

Hamisch C, Ruge M, Kellermann S et al (2017) Impact of treatment on survival of patients with secondary glioblastoma. J Neurooncol 133(2):309–313. https://doi.org/10.1007/s11060-017-2415-yCrossRefPubMed

11.

Hamza MA, Kamiya-Matsuoka C, Liu D, Yuan Y et al (2016) Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neuro-Oncol. 126(3):527–533. https://doi.org/10.1007/s11060-015-1992-xCrossRef

12.

Freedman RA, Wirth LJ, Chirieac LR, Huang EC (2007) Glioblastoma in a patient with early-stage tonsil cancer. J Clin Oncol 25(19):2848–2850. https://doi.org/10.1200/jco.2007.11.3530CrossRefPubMed

13.

Raufi A, Alsharedi M, Khelfa Y, Tirona M (2017) Bilateral triple-negative invasive breast cancer with a BRCA2 mutation, and glioblastoma: a case report and literature review. J Breast Cancer 20(1):108–111. https://doi.org/10.4048/jbc.2017.20.1.108CrossRefPubMedPubMedCentral

14.

Poyhonen L, Heikkinen J, Vehkalahti I (1979) Two different primary tumours of the brain in a patient with breast cancer. Eur J Nucl Med 4(6):483–484CrossRefPubMed

15.

Boukerroucha M, Josse C, Segers K et al (2015) BRCA1 germline mutation and glioblastoma development: report of cases. BMC Cancer 15:181. https://doi.org/10.1186/s12885-015-1205-1CrossRefPubMedPubMedCentral

16.

Nagane M, Shibui S, Nishikawa R, Oyama H, Nakanishi Y, Nomura K (1996) Triple primary malignant neoplasms including a malignant brain tumor: report of two cases and review of the literature. Surg Neurol 45(3):219–229CrossRefPubMed

17.

Piccirilli M, Salvati M, Bistazzoni S et al (2005) Glioblastoma multiforme and breast cancer: report on 11 cases and clinico-pathological remarks. Tumori 91(3):256–260CrossRefPubMed

18.

Nguyen HS, Doan NB, Gelsomino M et al (2019) Management and survival trends for adult patients with malignant gliomas in the setting of multiple primary tumors: a population based analysis. J Neurooncol 141(1):213–221. https://doi.org/10.1007/s11060-018-03028-4CrossRefPubMed

19.

Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310(17):1842–1850. https://doi.org/10.1001/jama.2013.280319CrossRefPubMed

20.

Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170(5):1445–1453. https://doi.org/10.2353/ajpath.2007.070011CrossRefPubMedPubMedCentral

21.

Li R, Li H, Yan W et al (2015) Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. Oncotarget 6(9):7318–7324. https://doi.org/10.18632/oncotarget.3440CrossRefPubMedPubMedCentral

22.

Curtis RE, Freedman DM, Ron E et al (eds) (2006) New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute

23.

Breslow NEN (1987) Statistical methods in cancer research: volume II—the design and analysis of cohort studies. IARC Sci Pub 82:1–406

24.

Scarbrough PM, Akushevich I, Wrensch M, Il’yasova D (2014) Exploring the association between melanoma and glioma risks. Ann Epidemiol 24(6):469–474. https://doi.org/10.1016/j.annepidem.2014.02.010CrossRefPubMedPubMedCentral

25.

Schad F, Thronicke A, Steele ML et al (2018) Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L in addition to chemotherapy, a real-world observational multicenter analysis. PloS One. 13(8):e0203058–e0203058. https://doi.org/10.1371/journal.pone.0203058CrossRefPubMedPubMedCentral

26.

Steckley JL, Watling CJ, Ng W (2008) Glioblastoma in a patient with a hereditary cancer syndrome. Can J Neurol Sci 35(1):98–101. https://doi.org/10.1017/s0317167100007642CrossRefPubMed

27.

Vienne-Jumeau A, Tafani C, Ricard D (2019) Environmental risk factors of primary brain tumors: a review. Rev Neurol (Paris) 175(10):664–678. https://doi.org/10.1016/j.neurol.2019.08.004CrossRefPubMed

Title: Risk of developing glioblastoma following non-CNS primary cancer: a SEER analysis between 2000 and 2018
Authors: David Y. A. Dadey
Zachary A. Medress
Mayur Sharma
Beatrice Ugiliweneza
Dengzhi Wang
Adrian Rodrigues
Jonathon Parker
Eric Burton
Brian Williams
Summer S. Han
Maxwell Boakye
Stephen Skirboll
Publication date: 04-10-2023
Publisher: Springer US
Keywords: Glioblastoma
Glioblastoma
Glioblastoma
Melanoma
Melanoma
Published in: Journal of Neuro-Oncology / Issue 3/2023
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-023-04460-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Risk of developing glioblastoma following non-CNS primary cancer: a SEER analysis between 2000 and 2018

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2023

Advancing personalized prognosis in atypical and anaplastic meningiomas through interpretable machine learning models

Long-term clinical outcomes of stereotactic radiotherapy for bilateral vestibular schwannomas in neurofibromatosis type 2 patients

Sexually dimorphic effect of H-ferritin genetic manipulation on survival and tumor microenvironment in a mouse model of glioblastoma

The impact of opioid administration for post gamma knife radiosurgery frame removal: a prospective quality-improvement study

Seizure outcomes after resection of primary brain tumors in pediatric patients: a systematic review and meta-analysis

Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses